The Dynamic Use of EGFR Mutation Analysis in Cell-Free DNA as a Follow-Up Biomarker during Different Treatment Lines in Non-Small-Cell Lung Cancer Patients

Figure 2

(a) Upper: longitudinal study of EGFR mutational levels (SQI) at baseline (), during treatment at the moment of the best response (), and at progression () of the disease. Lower: longitudinal study of EGFR mutational levels (SQI) considering therapy with either EGFR-TKIs (Basal, ; B.R., ; and Progres., ) or chemotherapy (Basal, ; B.R., ; and Progress, ). (b) Evolution of the EGFR mutational levels (SQI) in a patient during chemotherapy (docetaxel) treatment.

(a)

(b)